š£ Call for Papers
A Collection in Ther Adv Med Oncol focuses on #ADCs in gynecologic cancers, including ovarian, endometrial, and cervical malignancies. We welcome clinically relevant research and reviews.
šļø Deadline: 26 Feb 2027
buff.ly/30K8r13
#GynecologicOncology #CancerResearch #OpenCall
š A multicenter phase II randomized trial evaluates Endostar + concurrent chemoradiotherapy in locally advanced cervical cancer.
š Read the full article: buff.ly/mQhOTsg
#CervicalCancer #OncologyResearch #ClinicalTrials #Radiotherapy
š This study explores afatinib dose optimization to improve outcomes while reducing toxicities in advanced EGFRāmutated NSCLC patients in Vietnam.
š buff.ly/XucLdR2
#LungCancer #NSCLC #EGFR #TargetedTherapy #Oncology
How do physicians approach treatment decisions for young patients with HR+, HER2ā early #breastcancer? This Latin American survey provides insights into realāworld clinical practice.
š buff.ly/isnY3xJ
#BreastCancer #YoungPatients #ClinicalPractice #Oncology
š£ Call for Papers ā Submit to our Special Collection on:
Tumor Microenvironment in GI Cancers
š¬ Focus: clinically actionable biomarkers & therapeutic insights
š Clinical + translational research encouraged
š Deadline: 15 March 2027
š buff.ly/dpUqDMk
#CallForPapers #PrecisionOncology
š¢ This phase Ib/II study investigates the addition of neoadjuvant neratinib to standard therapy in patients with inflammatory #breastcancer, including those with HER2+ and HR+/HER2ā disease across stage III and IV settings.
š Read the full article:
buff.ly/bFwUuVM
#InflammatoryBreastCancer #HER2 #
šØ Call for Papers
The KRAS era is here - now we need strategies to anticipate & overcome resistance in pancreatic cancer.
Submit by Mar 1, 2027: KRAS pathways, combos, resistance mechanisms, new targets & models.
š buff.ly/eMwzb2N
#PDAC #KRAS #TargetedTherapy #CancerResearch
A large French multicenter cohort study examines how age influences clinical characteristics, treatment patterns, and outcomes in #BiliaryTractCancer, highlighting differences in unresectable disease and comparable survival after resection.
buff.ly/6PIVm3G
#Cholangiocarcinoma #GeriatricOncology
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
š Nationwide realāworld data reveal how treatment gaps are linked to survival outcomes in #HepatocellularCarcinoma, highlighting unmet needs in routine care.
š buff.ly/BF3QeGz
#HCC #LiverCancer #CancerOutcomes #RealWorldEvidence
A narrative review summarises recent advances and key trials of radionuclide therapies, including Ā²Ā²Ā³Ra, Ā¹ā·ā·Luālabelled agents, and emerging Ī±āemitters, in metastatic castrationāresistant #ProstateCancer.
Ther Adv Med Oncol
buff.ly/XQWUg2J
#RadionuclideTherapy
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
The treatment of metastatic castration-resistant prostate cancer (mCRPC) remains a huge challenge. Newer radionuclides, such as 223Ra, 177Lu, 225Ac, etc., have ...
